

EXAMINER: Mish DATE CONSIDERED: 1-20-05  
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

AUG 19 2002

PTO/SB/08A (10-01)

Approved for [redacted] through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

## **Complete if Known**

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10/017,327          |
| Filing Date            | December 6, 2001    |
| First Named Inventor   | Charles A NICOLETTE |
| Art Unit               | 1645                |
| Examiner Name          | Not Yet Assigned    |
| Attorney Docket Number | GZ 2101.20          |

## **U.S. PATENT DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Document Number<br>Number - Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YY | Name of Patentee or<br>Application of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages or<br>Relevant Figures Appear |
|-----------------------|--------------------------|---|------------------------------|--|---|
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |
|                       |                          | US-   |                              |  |   |

RECEIVED

AUG 21 2002

TECH CENTER 1600/2900

## **FOREIGN PATENT DOCUMENTS**

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YY | Name of Patentee or<br>Application of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sup>6</sup> |
|-----------------------|--------------------------|--|------------------------------|---|---|----------------|
| my                    | 1                        | WO 97/34613  | 09-25-97                     | University of Virginia                                  |   |                |
|                       | 2                        | WO 00/20457 A  | 04-13-00                     | Genzyme Corp.   |   |                |
|                       | 3                        | WO 01/92294 A  | 12-06-01                     | Genzyme Corp.   |   |                |
|                       | 4                        | WO 01/92306 A  | 12-06-01                     | Genzyme Corp.   |   |                |
|                       |                          |  |                              |   |   |                |
|                       |                          |  |                              |   |   |                |
|                       |                          |  |                              |   |   |                |
|                       |                          |  |                              |   |   |                |
|                       |                          |  |                              |   |   |                |
|                       |                          |  |                              |   |   |                |
|                       |                          |  |                              |   |   |                |
|                       |                          |  |                              |   |   |                |

Examiner's  
Signature

msob 7

Date

Considered

1-20-05

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

**COPY OF PAPERS  
ORIGINALLY FILED**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

|       |   |    |   |
|-------|---|----|---|
| Sheet | 1 | of | 1 |
|-------|---|----|---|

**Complete if Known**

|                               |                             |
|-------------------------------|-----------------------------|
| <b>Application Number</b>     | <b>10/017,327</b>           |
| <b>Filing Date</b>            | <b>December 6, 2001</b>     |
| <b>First Named Inventor</b>   | <b>Charles A. NICOLETTE</b> |
| <b>Art Unit</b>               | <b>1645</b>                 |
| <b>Examiner Name</b>          | <b>Not Yet Assigned</b>     |
| <b>Attorney Docket Number</b> | <b>GZ 2101.20</b>           |

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

RECEIVED

Aug 21 2002

TECH CENTER 1600/2900

**Examiner's  
Signature**

Date Considered

1-15-05

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

**COPY OF PAPERS  
ORIGINALLY FILED**

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/017,327       |
| Filing Date            | December 6, 2001 |
| First Named Inventor   | Nicolette        |
| Art Unit               | 1645             |
| Examiner Name          | Unassigned       |
| Attorney Docket Number | GZ 2101.20       |

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No.† | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published | 7 |
|--------------------|-----------|---|---|
| W                  | 1         | PINCHEIRA R. ET AL.: "Identification of a 170-kDa protein over-expressed in lung cancers." BRITISH JOURNAL OF CANCER (2001) 84(11):1520-1527.   |   |
| J                  | 2         | ROTHE MARCUS ET AL.: "Eukaryotic Initiation factor 3 p110 mRNA is overexpressed in testicular seminomas." AMERICAN JOURNAL OF PATHOLOGY (2001) 157(5):1597-1604.  |   |
|                    | 3         |   |   |
|                    | 4         |   |   |
|                    | 5         |   |   |
|                    | 6         |   |   |
|                    | 7         |   |   |
|                    | 8         |   |   |
|                    | 9         |   |   |
|                    | 10        |   |   |
|                    | 11        |   |   |
|                    | 12        |   |   |
|                    | 13        |   |   |
|                    | 14        |   |   |
|                    | 15        |   |   |
|                    | 16        |   |   |
|                    | 17        |   |   |
|                    | 18        |   |   |
|                    | 19        |   |   |
|                    | 20        |   |   |
|                    | 21        |   |   |
|                    | 22        |   |   |
|                    | 23        |   |   |
|                    | 24        |   |   |

Examiner's  
Signature

[Signature]

Date  
Considered

1-20-01

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of

1

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/017,327       |
| Filing Date            | December 6, 2001 |
| First Named Inventor   | Nicolette        |
| Art Unit               | 1845             |
| Examiner Name          | Unassigned       |
| Attorney Docket Number | GZ 2101.20       |

**U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number<br>Number - Kind Code <sup>2</sup> (if known) | Publication Date<br>MM-DD-YY | Name of Patentee or<br>Application of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages or<br>Relevant Figures Appear |
|--------------------|-----------------------|---|------------------------------|--|---|
|                    | 1                     | US-   |                              |  |   |
|                    | 2                     | US-   |                              |  |   |
|                    | 3                     | US-   |                              |  |   |
|                    | 4                     | US-   |                              |  |   |
|                    | 5                     | US-   |                              |  |   |
|                    | 6                     | US-   |                              |  |   |
|                    | 7                     | US-   |                              |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document<br>Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) | Publication Date<br>MM-DD-YY | Name of Patentee or<br>Application of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages or<br>Relevant Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|--|------------------------------|--|---|----------------|
|                    | 8                     | WO 00/36144 A  | 08-22-00                     | Jorma  | Entire doc.   |                |
|                    | 9                     | WO 01/92307 A  | 12-08-01                     | Genzyme  | Entire doc.   |                |
|                    | 10                    |  |                              |  |   |                |
|                    | 11                    |  |                              |  |   |                |
|                    | 12                    |  |                              |  |   |                |
|                    | 13                    |  |                              |  |   |                |
|                    | 14                    |  |                              |  |   |                |
|                    | 15                    |  |                              |  |   |                |
|                    | 16                    |  |                              |  |   |                |
|                    | 17                    |  |                              |  |   |                |
|                    | 18                    |  |                              |  |   |                |
|                    | 19                    |  |                              |  |   |                |
|                    | 20                    |  |                              |  |   |                |

Examiner's  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

Form PTO-1449

Docket No. GZ 2101.20

Appl. No. 10/017,327

INFORMATION DISCLOSURE  
STATEMENT

Applicant(s)

Charles A. NICOLETTE

Filing Date: December 6, 2001

Group Art Unit: Not Yet Assigned

(use several sheets if necessary)

## U.S. PATENT DOCUMENTS

| Examiner<br>Initials | Ref.<br>No. | Date     | Document No. | Name              | Class | Subclass | Filing Date<br>(if appropriate) |
|----------------------|-------------|----------|--------------|-------------------|-------|----------|---------------------------------|
| my                   | 1.          | 07/28/87 | 4,683,195    | Mullis et al.     |       |          |                                 |
|                      | 2.          | 07/28/87 | 4,683,202    | Mullis            |       |          |                                 |
|                      | 3.          | 06/28/88 | 4,754,065    | Levenson et al.   |       |          |                                 |
|                      | 4.          | 01/24/89 | 4,800,159    | Mullis et al.     |       |          |                                 |
|                      | 5.          | 08/08/95 | 5,440,013    | Kahn              |       |          |                                 |
|                      | 6.          | 11/17/98 | 5,837,249    | Heber-Katz et al. |       |          |                                 |

## FOREIGN PATENT DOCUMENTS

| Examiner<br>Initials | Ref.<br>No. | Date     | Document No. | Name  | Class | Subclass | Translation<br>YES NO |
|----------------------|-------------|----------|--------------|---|-------|----------|-----------------------|
| zy                   | 7.          | 08/01/96 | WO 96/23060  | The Government of the<br>United States of America |       |          |                       |

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

| Examiner<br>Initials | Ref.<br>No. | Title  |
|----------------------|-------------|--|
| my                   | 8.          | Altman, J.D. et al., "Phenotypic analysis of antigen-specific T lymphocytes" (1996) <i>Science</i> 274(5284):94-96   |
|                      | 9.          | Bertoni, R. et al., "Human class I supertypes and CTL repertoires extend to chimpanzees" (1998) <i>J. Immunol.</i> 161:4447-4455   |
|                      | 10.         | Boczkowski, D. et al., "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo" (1996) <i>J. Exp. Med.</i> 184:465-472   |
|                      | 11.         | Bordignon, C. et al., "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" (1989) <i>PNAS USA</i> 86:6748-6752 |
|                      | 12.         | Carter, B.J., "Adeno-associated virus vectors" (1992) <i>Curr. Op. Biotechnol.</i> 3:533-539   |
|                      | 13.         | Caruso, A. et al., "Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation" (1997) <i>Cytometry</i> 27:71-76   |
|                      | 14.         | Correll, P.H. et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells" (1989) <i>PNAS USA</i> 86:8912-8916                     |
|                      | 15.         | Coulie, P.G., "Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?" (1997) <i>Molec. Med. Today</i> 3:261-268  |
|                      | 16.         | Culver, K. et al., "Lymphocytes as cellular vehicles for gene therapy in mouse and man" (1991) <i>PNAS USA</i> 88:3155-3159  |
|                      | 17.         | Dharanipragada, R. et al., "The absolute configuration of an intermediate in the asymmetric synthesis of unusual amino acids" (1992) <i>Acta. Cryst.</i> C48:1239-1241   |
| ✓                    | 18.         | Dharanipragada, R. et al., "Synthetic linear and cyclic glucagon antagonists" (1993) <i>Int. J. Peptide Protein Res.</i> 42(1):68-77   |


EXAMINER:

Mian

DATE CONSIDERED:

1-20-05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.




|                                   |   |                                      |                                  |
|-----------------------------------|---|--------------------------------------|----------------------------------|
| Form PTO-1449                     |   | Docket No. GZ 2101.20                | Appl. No. 10/017,327             |
| INFORMATION DISCLOSURE STATEMENT  |   | Applicant(s)<br>Charles A. NICOLETTE |                                  |
| (use several sheets if necessary) |   | Filing Date: December 6, 2001        | Group Art Unit: Not Yet Assigned |
| 19.                               | DiMaio, J. et al., "Synthesis of chiral piperazin-2-ones as model peptidomimetics" (1989) <i>J. Chem. Soc. Perkin Trans. 1</i> (9):1687-1689  |                                      |                                  |
| 20.                               | Feltkamp, M.C.W. et al., "Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" (1995) <i>Immunol. Lett.</i> 47:1-8   |                                      |                                  |
| 21.                               | Ferguson, et al. "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" (1988) <i>Ann. Rev. Biochem.</i> 57:285-320  |                                      |                                  |
| 22.                               | Fujihashi, K. et al., "Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells" (1993) <i>J. Immunol. Meth.</i> 160:181-189   |                                      |                                  |
| 23.                               | Garvey D.S. et al., "3,4-disubstituted $\gamma$ -lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine" (1990) <i>J. Org. Chem.</i> 55(3):936-940   |                                      |                                  |
| 24.                               | Hruby, V.J., "Conformational restrictions of biologically active peptides via amino acid side chain groups" (1982) <i>Life Sciences</i> 31:189-199  |                                      |                                  |
| 25.                               | Hruby, V.J. et al. "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations" (1990) <i>Biochem J.</i> 268:249-262   |                                      |                                  |
| 26.                               | Isakov, N. et al., "ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity" (1995) <i>J. Exp. Med.</i> 181:375-380   |                                      |                                  |
| 27.                               | Jones, R.C.F. and G.J. Ward, "Amide bond isosteres: imidazolines in pseudopeptide chemistry" (1988) <i>Tetrahedron Lett.</i> 29(31):3853-3856   |                                      |                                  |
| 28.                               | Kahn, M. and S. Bertenshaw, "The incorporation of $\beta$ -turn prosthetic units into merrifield solid phase peptide synthesis" (1989) <i>Tetrahedron Lett.</i> 30(18):2317-2320  |                                      |                                  |
| 29.                               | Karlsson, S. et al., "Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors" (1986) <i>The EMBO J.</i> 5(9):2377-2385   |                                      |                                  |
| 30.                               | Kawakami, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" (1994) <i>PNAS USA</i> 91(9):3515-3519   |                                      |                                  |
| 31.                               | Kazmierski, W. M. and V.J. Hruby, "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of $\alpha,\beta$ -dimethyl-phenylalanine and $\alpha,\beta$ -dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" (1991) <i>Tetrahedron Lett.</i> 32(41):5769-5772 |                                      |                                  |
| 32.                               | Kazmierski, W.M. et al., "Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity" (1991) <i>J. Am. Chem. Soc.</i> 113:2275-2283  |                                      |                                  |
| 33.                               | Kemp, D.S. and P.E. McNamara, "Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), a potent $\beta$ -turn-inducing dipeptide analogue" (1985) <i>J. Org. Chem.</i> 50:5834-5838   |                                      |                                  |
| 34.                               | Kemp, D.S. and B.R. Bowen, "Conformational analysis of peptide-functionalized diacylaminoepindolidiones $^1\text{H}$ NMR evidence for $\beta$ -sheet formation" (1988) <i>Tetrahedron Lett.</i> 29(40):5081-5082  |                                      |                                  |
| 35.                               | Kemp, D.S. and W.E. Stites, "A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1, 6-diaza-cyclodeca-2, 7-dione The dilactam of L- $\alpha$ , $\gamma$ -diaminobutyric acid and D-glutamic acid: A $\beta$ -turn template" (1988) <i>Tetrahedron Lett.</i> 29(40):5057-5060                          |                                      |                                  |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.




|                                   |     |   |                                  |
|-----------------------------------|-----|---|----------------------------------|
| Form PTO-1449                     |     | Docket No. GZ 2101.20   | Appl. No. 10/017,327             |
| INFORMATION DISCLOSURE STATEMENT  |     | Applicant(s)<br>Charles A. NICOLETTE  |                                  |
| (use several sheets if necessary) |     | Filing Date: December 6, 2001   | Group Art Unit: Not Yet Assigned |
| 27                                | 36. | Kemp, D.S. and T.P. Curran, "(2, 5S, 8S, 11S)-1-acetyl-1, 4-diaza-3-keto-5-carboxy-10-thia-tricyclo-[2.8.0 <sup>4,8</sup> ]-ridecane, 1 the preferred conformation of 1 (1=αtemp-OH) and its peptide conjugates αtemp-L-(Ala) <sub>n</sub> -OR (n=1 to 4) and α-temp-L-Ala-L-Phe-Lys(εBoc)-L-Lys(ε-Boc)-NHMe studies of templates for α-helix formation" (1988) <i>Tetrahedron Lett.</i> 29(39):4935-4938 |                                  |
|                                   | 37. | Kemp, D.S. and J.S. Carter, "Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives) as γ-turn templates" (1989) <i>J. Org. Chem.</i> 54:109-115   |                                  |
|                                   | 38. | McGrory, W.J. et al., "Short communications: A simple technique for the rescue of early region I mutation into infectious human adenovirus type 5" (1988) <i>Virology</i> 163:614-617   |                                  |
|                                   | 39. | Merifield, R.B., "New approaches to the chemical synthesis of peptides" (1967) <i>Recent Progress in Hormone Res.</i> 23:451-482  |                                  |
|                                   | 40. | Miyake, A. et al., "Synthesis and angiotensin converting enzyme inhibitory activity of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives" (1984) <i>J. Takeda Res. Labs.</i> 43(3/4):53-76   |                                  |
|                                   | 41. | Mosier, D.E. et al., "Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160" (1993) <i>PNAS. USA</i> 90:2443-2447   |                                  |
|                                   | 42. | Muzyczka, "Use of adeno-associated virus as a general transduction vector for mammalian cells" (1992) <i>Curr. Top. Microbiol. Immunol.</i> 158:97-129  |                                  |
|                                   | 43. | Nagai, U. and K. Sato, "Synthesis of a bicyclic dipeptide with the shape of β-turn central part" (1985) <i>Tetrahedron Lett.</i> 26(5):647-650  |                                  |
|                                   | 44. | Nair, S. et al., "Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro" (1992) <i>J. Exp. Med.</i> 175:609-612   |                                  |
|                                   | 45. | Olson, G.L. et al., "Design and synthesis of a protein β-turn mimetic" (1990) <i>J. Am. Chem. Soc.</i> 112:323-333  |                                  |
|                                   | 46. | Paglia, P. et al., "Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo" (1996) <i>J. Exp. Med.</i> 183:317-322   |                                  |
|                                   | 47. | Pardoll, D.M., "Cancer vaccines" (1998) <i>Nature Med.</i> 4(5 Suppl.):525-531  |                                  |
|                                   | 48. | Parker, et al., "Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2" (1992) <i>J. Immunol.</i> 149(11):3580-3587   |                                  |
|                                   | 49. | Parker, K.C. et al. (1995) "Peptide Binding to MHC Class I Molecules: Implications for Antigenic Peptide Prediction" <i>Immunol. Res.</i> 14:34-57  |                                  |
|                                   | 50. | Parkhurst, M.R. et al., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues" (1996) <i>J. Immunol.</i> 157:2539-2548   |                                  |
|                                   | 51. | al-Ramadi, B.K. et al., "Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR" (1992) <i>J. Immunol.</i> 155(2):662-673   |                                  |
|                                   | 52. | Rill, D.R. et al., "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" (1992) <i>Blood</i> 79(10):2694-2700   |                                  |
|                                   | 53. | Rouse, R.J.D. et al., "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins" (1994) <i>J. Virol.</i> 68(9):5685-5689  |                                  |
|                                   | 54. | Salazar, E. et al., "Agonist peptide from a cytotoxic T-lymphocyte epitope of human carcinoembryonic antigen stimulates production of TC1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide" (2000) <i>Int. J. Cancer</i> 85:829-838  |                                  |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.





|                                   |     |   |                                  |
|-----------------------------------|-----|---|----------------------------------|
| Form PTO-1449                     |     | Docket No. GZ 2101.20   | Appl. No. 10/017,327             |
| INFORMATION DISCLOSURE STATEMENT  |     | Applicant(s)<br>Charles A. NICOLETTE  |                                  |
| (use several sheets if necessary) |     | Filing Date: December 6, 2001   | Group Art Unit: Not Yet Assigned |
| my                                | 55. | Samanen, J. et al., "5,5-dimethylthiazolidine-4-carboxylic acid (DTC) as a proline analog with restricted conformation" (1990) <i>Int. J. Peptide Protein Res.</i> 35:501-509   |                                  |
|                                   | 56. | Schlesinger, S. and T.W. Dubensky, Jr., "Alphavirus vectors for gene expression and vaccines" (1999) <i>Curr Opin Biotechnol.</i> 10(5):434-439   |                                  |
|                                   | 57. | Sette, A. et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes" (1994) <i>J. Immunol.</i> 153(12):5586-5592   |                                  |
|                                   | 58. | Shirai, M. et al., "CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1" (1995) <i>J. Immunol.</i> 154:2733-2742   |                                  |
|                                   | 59. | Stuber, G. et al., "HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class 1 stabilization assay. Low proportion of binding motifs for several HLA class 1 alleles in EBNA-1" (1995) <i>Int. Immunol.</i> 7(4):653-663 |                                  |
|                                   | 60. | Tan, L. et al., "An improved assembly assay for peptide binding to HLA-B*2705 and H-2K*class I MHC molecules" (1997) <i>J. Immunol. Meth.</i> 209(1):25-36  |                                  |
|                                   | 61. | Tanguay, S. and J.J. Killion, "Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells" (1994) <i>Lymphokine Cytokine Res.</i> 13(4):259-263   |                                  |
|                                   | 62. | Valmori, D. et al., "Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue" (2000) <i>J. Immunol.</i> 164(2):1125-1131  |                                  |
|                                   | 63. | van der Burg, S.H. et al., "Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability" (1996) <i>J. Immunol.</i> 156:3308-3314   |                                  |
|                                   | 64. | Ware, C.F. et al., "Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line" (1983) <i>J. Immunol.</i> 131(3):1312-1317   |                                  |
|                                   | 65. | Wilchek, M. and E.A. Bayer, "The avidin-biotin complex in bioanalytical applications" (1988) <i>Anal. Biochem.</i> 171:1-32   |                                  |
|                                   | 66. | Ying, H. et al., "Cancer therapy using a self-replicating RNA vaccine" (1999) <i>Nat. Med.</i> 5(7):823-827   |                                  |
|                                   | 67. | Zabrocki, J. et al., "Conformational mimicry. 1. 1,5-disubstituted tetrazole ring as a surrogate for the cis amide bond" (1988) <i>J. Am. Chem. Sci.</i> 110:5875-5880  |                                  |
|                                   | 68. | Zechel, C. et al., "Synthetic glucagon antagonists and partial agonists" (1991) <i>Int. J. Pep. Protein Res.</i> 38(2):131-138  |                                  |
|                                   | 69. | Zuegel, et al., "Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues" (1998) <i>J. Immunol.</i> 161(4):1705-1709  |                                  |
| ✓                                 | 70. | Zweerink, H.J. et al., "Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells" (1993) <i>J. Immunol.</i> 150(5):1763-1771   |                                  |

|  |                          |
|--|--------------------------|
| EXAMINER: <i>Misrovi</i>   | DATE CONSIDERED: 1-20-05 |
| EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. |                          |